BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2019

View Archived Issues

CD47 prevents gene therapy from being eaten

Read More

Gallbladder cancer murine models developed from organoid cell lines

Read More

Circulating elafin as potential new biomarker of prediabetic condition

Read More

Urinary Cyr61 and TFF3 as promising new biomarkers in patients with colorectal cancer

Read More

Akero Therapeutics initiates phase IIa study of AKR-001 for the treatment of NASH

Read More

Expansion Therapeutics initiates phase I trial of ERX-963 in adults with DM1

Read More

Polyphor, University of Zurich awarded grant to develop new class of LPS-inhibiting antibiotics

Read More

SNX29 variation plays a role in vasodilator therapy response in PAH

Read More

Strep genome research expedites vaccine development

Read More

TRPV1 as a novel target in gastric cancer therapy

Read More

Gut-derived live bacterial strains found to modulate neuroinflammation and neurodegeneration in PD

Read More

Medshine Discovery divulges mTORC1 and mTORC2 inhibitors

Read More

Sumitomo Dainippon Pharma patents TLR7 antagonists

Read More

Xeomin approved in E.U. for treatment of chronic sialorrhea in adults

Read More

German researchers present new adenosine A2A receptor ligands

Read More

Metacrine reports phase Ib interim data on FXR agonist MET-409 in NASH

Read More

Jubilant Biosys describes PD-1/PD-L1 interaction inhibitors

Read More

Phase III KALM-1 study of Korsuva in hemodialysis patients with pruritus meets primary endpoint

Read More

Merck & Co. discovers IDO1 inhibitors

Read More

Michael J. Fox Foundation awards Casma Therapeutics grant to advance PD drug development

Read More

NRF2 gene polymorphism tied to emphysema development in smokers

Read More

Amicus and University of Pennsylvania expand gene therapy collaboration

Read More

AdCh3NSmut1/MVA-NSmut did not protect against HCV infection in phase I/II trial

Read More

Mereo reports 6-month open-label data from phase IIb study of BPS-804 in osteogenesis imperfecta

Read More

Phase III QUARTZ study of QMF-149 in inadequately controlled asthma meets primary endpoint

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing